EAST BRUNSWICK, N.J., Sept. 13, 2006 (PRIMEZONE) -- Phase IV studies are continuing to increase and based on a Tufts study, 73% of recent new drug approvals received FDA requests for post-marketing studies. The median cost of conducting these studies are also skyrocketing. Another costly and critical factor in conducting clinical trials, Phase I-IV, is the patient and investigator recruitment area which is one the most time consuming and difficult tasks within drug development.
